Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.
Ayeni D., Miller B., Kuhlmann A., Ho P.C., Robles-Oteiza C., Gaefele M., Levy S., de Miguel F.J., Perry C., Guan T. et al., 2019/07/10. Journal for immunotherapy of cancer, 7 (1) p. 172. Peer-reviewed.